Top

CardioVascular and Interventional Radiology

Published in:

01-04-2024 | Kidney Cancer | Clinical Investigation

Percutaneous Microwave Ablation Versus Robot-Assisted Partial Nephrectomy for Stage I Renal Cell Carcinoma: A Propensity-Matched Cohort Study Focusing Upon Long-Term Follow-Up of Oncologic Outcomes

Authors: David-Dimitris Chlorogiannis, Zisis Kratiras, Evgenia Efthymiou, Napoleon Moulavasilis, Nikolaos Kelekis, Michail Chrisofos, Konstandinos Stravodimos, Dimitris K. Filippiadis

Published in: CardioVascular and Interventional Radiology | Issue 5/2024

Abstract

Purpose

To retrospectively compare long-term oncologic outcomes of percutaneous computed tomography-guided microwave ablation (MWA) and robot-assisted partial nephrectomy (RAPN) for the treatment of stage 1 (T1a and T1b) renal cell carcinoma (RCC) patients.

Materials and Methods

Institutional database research identified all T1 RCC patients who underwent either MWA or RAPN. Models were adjusted with propensity score matching. Kaplan–Meier log-rank test analyses and Cox proportional hazard regression models were used to compare the oncologic outcomes. Patient and tumor characteristics, technical success as well as oncologic outcomes were evaluated and compared between the 2 groups.

Results

After propensity score matching, a total of 71 patients underwent percutaneous MWA (mean age 70 ± 10 years) and 71 underwent RAPN (mean age 60 ± 9 years). At 8-year follow-up, the estimated survival rates for MWA cohort were 98% (95% confidence interval [CI] 95–100%) for overall survival, 97% (95% CI 93–100%) for recurrence-free survival, and 97% (95% CI 93–100%) for metastasis-free survival. The matched cohort that underwent RAPN exhibited survival rates of 100% (95% CI 100–100%) for overall survival, 98% (95% CI 94–100%) for recurrence-free survival, and 98% (95% CI 94–100%) for metastasis-free survival. After performing log-rank testing, these rates were not significantly different (p values of 0.44, 0.67, and 0.67, respectively).

Conclusion

The results of the present study suggest that both MWA and RAPN are equally effective in terms of oncologic outcome for the treatment of T1 RCC.

Available only for authorised users

Bukavina L, Bensalah K, Bray F, et al. Epidemiology of renal cell carcinoma: 2022 update. Eur Urol. 2022;82:529–42. https://doi.org/10.1016/j.eururo.2022.08.019.CrossRefPubMed

Du Z, Chen W, Xia Q, et al. Trends and projections of kidney cancer incidence at the global and national levels, 1990–2030: a Bayesian age-period-cohort modeling study. Biomark Res. 2020;8:16. https://doi.org/10.1186/s40364-020-00195-3.CrossRefPubMedPubMedCentral

Lavallée LT, Tanguay S, Jewett MA, et al. Surgical management of stage T1 renal tumors in Canadian academic centers. Can Urol Assoc J. 2015;9:99. https://doi.org/10.5489/cuaj.2598.CrossRefPubMedPubMedCentral

Sun M, Bianchi M, Trinh Q-D, et al. Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities. BJU Int. 2013;111:67–73. https://doi.org/10.1111/j.1464-410X.2012.11254.x.CrossRefPubMed

Yanagisawa T, Mori K, Kawada T, et al. Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: a systematic review and meta-analysis. Urol Oncol Semin Orig Invest. 2022;40:315–30. https://doi.org/10.1016/j.urolonc.2022.04.002.CrossRef

NCCN Guidelines Version 1.2024 Kidney Cancer, Robert Mozer et al.

Campbell SC, Clark PE, Chang SS, et al. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part I. J Urol. 2021;206:199–208. https://doi.org/10.1097/JU.0000000000001911.CrossRefPubMed

Finelli A, Ismaila N, Bro B, et al. Management of small renal masses: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2017;35:668–80. https://doi.org/10.1200/JCO.2016.69.9645.CrossRefPubMed

Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009;182:844–53. https://doi.org/10.1016/j.juro.2009.05.035.CrossRefPubMed

10.

Puijk RS, Ahmed M, Adam A, et al. Consensus guidelines for the definition of time-to-event end points in image-guided tumor ablation: results of the SIO and DATECAN initiative. Radiology. 2021;301:533–40. https://doi.org/10.1148/radiol.2021203715.CrossRefPubMed

11.

Filippiadis DK, Binkert C, Pellerin O, et al. Cirse quality assurance document and standards for classification of complications: the cirse classification system. Cardiovasc Intervent Radiol. 2017;40:1141–6. https://doi.org/10.1007/s00270-017-1703-4.CrossRefPubMed

12.

Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications. Ann Surg. 2009;250:187–96. https://doi.org/10.1097/SLA.0b013e3181b13ca2.CrossRefPubMed

13.

Yao XI, Wang X, Speicher PJ, et al. Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies. JNCI J Natl Cancer Inst. 2017. https://doi.org/10.1093/jnci/djw323.CrossRefPubMed

14.

Zhao Q-Y, Luo J-C, Su Y, et al. Propensity score matching with R: conventional methods and new features. Ann Transl Med. 2021;9:812–812.CrossRefPubMedPubMedCentral

15.

Rubin DB. Using propensity scores to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol. 2001;2:169–88. https://doi.org/10.1023/A:1020363010465.CrossRef

16.

Weight CJ, Lieser G, Larson BT, et al. Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours. Eur Urol. 2010;58:293–8. https://doi.org/10.1016/j.eururo.2010.04.033.CrossRefPubMed

17.

Weight CJ, Larson BT, Gao T, et al. Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology. 2010;76:631–7. https://doi.org/10.1016/j.urology.2009.11.087.CrossRefPubMed

18.

Li L, Zhu J, Shao H, et al. Long-term outcomes of radiofrequency ablation vs. partial nephrectomy for cT1 renal cancer: a meta-analysis and systematic review. Front Surg. 2023. https://doi.org/10.3389/fsurg.2022.1012897.CrossRefPubMedPubMedCentral

19.

Morkos J, Porosnicu Rodriguez KA, Zhou A, et al. Percutaneous cryoablation for stage 1 renal cell carcinoma: outcomes from a 10-year prospective study and comparison with matched cohorts from the national cancer database. Radiology. 2020;296:452–9. https://doi.org/10.1148/radiol.2020192325.CrossRefPubMed

20.

Filippiadis D, Mauri G, Marra P, et al. Percutaneous ablation techniques for renal cell carcinoma: current status and future trends. Int J Hyperth. 2019;36:21–30. https://doi.org/10.1080/02656736.2019.1647352.CrossRef

21.

Efthymiou E, Siatelis A, Liakouras C, et al. Computed tomography-guided percutaneous microwave ablation for renal cell carcinoma: impact of tumor size on the progression survival rates. Diagnostics. 2021;11:1618. https://doi.org/10.3390/diagnostics11091618.CrossRefPubMedPubMedCentral

22.

Lucignani G, Rizzo M, Ierardi AM, et al. Percutaneous microwave ablation is comparable to cryoablation for the treatment of T1a renal masses: results from a cross-sectional study. Clin Genitourin Cancer. 2022;20:e506–11. https://doi.org/10.1016/j.clgc.2022.07.004.CrossRefPubMed

23.

Castellana R, Natrella M, Fanelli G, et al. Efficacy and safety of MWA versus RFA and CA for renal tumors: a systematic review and meta-analysis of comparison studies. Eur J Radiol. 2023;165:110943. https://doi.org/10.1016/j.ejrad.2023.110943.CrossRefPubMed

24.

Panhelleux M, Balssa L, David A, et al. Evaluation of local control after percutaneous microwave ablation versus partial nephrectomy: a propensity score matched study. Prog Urol. 2023. https://doi.org/10.1016/j.purol.2023.09.021.CrossRef

25.

Efthymiou E, Velonakis G, Charalampopoulos G, et al. Computed tomography-guided percutaneous microwave ablation for renal cell carcinoma: evaluating the performance of nephrometry scores. Eur Radiol. 2023. https://doi.org/10.1007/s00330-023-09774-y.CrossRefPubMed

26.

Cazalas G, Klein C, Piana G, et al. A multicenter comparative matched-pair analysis of percutaneous tumor ablation and robotic-assisted partial nephrectomy of T1b renal cell carcinoma (AblatT1b study—UroCCR 80). Eur Radiol. 2023;33:6513–21. https://doi.org/10.1007/s00330-023-09564-6.CrossRefPubMed

27.

Shapiro DD, Wells SA, Best SL, et al. Comparing outcomes for patients with clinical T1b renal cell carcinoma treated with either percutaneous microwave ablation or surgery. Urology. 2020;135:88–94. https://doi.org/10.1016/j.urology.2019.09.024.CrossRefPubMed

28.

Yeaman C, Marchant R, Lobo JM, et al. Cost-effectiveness analysis: percutaneous microwave ablation vs robotic-assisted partial nephrectomy for small renal masses. Abdom Radiol. 2022;48:411–7. https://doi.org/10.1007/s00261-022-03692-1.CrossRef

29.

Junker T, Duus L, Rasmussen BSB, et al. Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review. Syst Rev. 2022;11:4. https://doi.org/10.1186/s13643-021-01868-2.CrossRefPubMedPubMedCentral

Title: Percutaneous Microwave Ablation Versus Robot-Assisted Partial Nephrectomy for Stage I Renal Cell Carcinoma: A Propensity-Matched Cohort Study Focusing Upon Long-Term Follow-Up of Oncologic Outcomes
Authors: David-Dimitris Chlorogiannis
Zisis Kratiras
Evgenia Efthymiou
Napoleon Moulavasilis
Nikolaos Kelekis
Michail Chrisofos
Konstandinos Stravodimos
Dimitris K. Filippiadis
Publication date: 01-04-2024
Publisher: Springer US
Keywords: Kidney Cancer
Kidney Cancer
Kidney Cancer
Nephrectomy
Nephrectomy
Nephrectomy
Metastasis
Renal Cancer
Published in: CardioVascular and Interventional Radiology / Issue 5/2024
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-024-03695-z

At a glance: The STEP trials

Springer Medicine

Percutaneous Microwave Ablation Versus Robot-Assisted Partial Nephrectomy for Stage I Renal Cell Carcinoma: A Propensity-Matched Cohort Study Focusing Upon Long-Term Follow-Up of Oncologic Outcomes

Abstract

Purpose

Materials and Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2024

Partial Splenic Embolization in Paediatric Sickle Cell Disease Patients with Hypersplenism

GPT-4's Performance on the European Board of Interventional Radiology Sample Questions

Efficacy of High-Dose Dexamethasone in Reducing the Symptoms of Postembolization Syndrome Following Prostatic Artery Embolization: Results of a Double-Blind Randomized Controlled Trial

Post-Embolization Syndrome After Prostatic Artery Embolization: Where are we, and Where to Next?

Establishing a Tailored Pulmonary Thromboembolism Response Team in Your Hospital: How did We do It?

Effect of Sarcopenia on the Increase in Liver Volume and Function After Portal Vein Embolization: A Comment